I've been taking quetiapine (Seroquel) since [DATE] and after a drug holiday restarted the full 150 mg dose, but I'm still experiencing marked drowsiness; shouldn't I have developed tolerance to its sedating effects by now?

Tolerance to Quetiapine's Sedating Effects Does Not Reliably Develop

You should not expect to develop tolerance to quetiapine's sedating effects, and restarting at your full 150 mg dose after a drug holiday was likely the cause of your persistent drowsiness. The sedation from quetiapine, particularly at doses used for sleep (typically 25-300 mg), tends to persist rather than diminish with continued use.

Why Tolerance Doesn't Develop to Quetiapine's Sedation

Quetiapine's sedative properties are fundamentally different from drugs where tolerance predictably occurs. While the evidence on opioids shows that tolerance develops to analgesic and euphoric effects but less so to respiratory depression 1, quetiapine's sedation operates through different mechanisms (primarily histamine H1 receptor antagonism and alpha-1 adrenergic blockade) that don't follow the same tolerance patterns.

The FDA label for quetiapine explicitly lists "drowsiness" and "sleepiness" as among the most common side effects in both adults and children/adolescents 2, with no mention of these effects diminishing over time. This persistent sedation is a feature, not a bug, when quetiapine is used off-label for insomnia.

The Evidence on Quetiapine and Sedation

Research consistently demonstrates that quetiapine's sedating effects remain throughout treatment:

• A systematic review and meta-analysis found that quetiapine improved sleep quality across multiple conditions, with effects observed at doses of 50-300 mg 3
• The sedation intensity varies by formulation and timing: Extended-release quetiapine produces significantly lower sedation 1-3 hours post-dose compared to immediate-release, but similar sedation 4-14 hours later 4
• Studies show quetiapine increases total sleep time by approximately 48 minutes compared to placebo, an effect that persists throughout treatment 3

The Drug Holiday Problem

Your drug holiday reset your physiological adaptation to the medication, making you essentially drug-naive again. When you restarted at the full 150 mg dose, you experienced the full sedating impact without the gradual titration that allows for some functional adaptation (not true pharmacological tolerance, but behavioral/functional adjustment).

The FDA label recommends gradual dose escalation: starting at 50 mg on day 1, increasing to 100 mg on day 2, then 200 mg on day 3, and 300 mg on day 4 for bipolar depression 2. You bypassed this titration by jumping directly to 150 mg.

What You Should Do

Reduce your dose immediately and retitrate upward slowly:

1. Drop to 25-50 mg tonight to establish a tolerable baseline
2. Increase by 25-50 mg every 3-7 days as tolerated, monitoring drowsiness
3. Take the dose 1-2 hours before desired sleep time to align peak sedation with bedtime
4. Consider switching to extended-release formulation if available, as it produces less intense early sedation 4

Critical Safety Warnings

The persistent drowsiness you're experiencing carries serious risks:

• Falls and injuries: Quetiapine significantly increases fall risk, particularly in the first few hours after dosing 2
• Orthostatic hypotension: Sudden drops in blood pressure when standing can cause fainting 2
• Impaired driving and cognitive function: The FDA label explicitly warns against driving or operating machinery until you know how quetiapine affects you 2

In older adults specifically, low-dose quetiapine for insomnia is associated with increased mortality (HR 3.1), dementia (HR 8.1), and falls (HR 2.8) compared to alternatives like trazodone 5. If you're over 65, this medication choice should be reconsidered entirely.

The Bigger Picture: Questionable Evidence for Off-Label Use

The use of quetiapine for insomnia lacks robust confirmatory evidence. A meta-epidemiological analysis found that 79% of off-label indications for quetiapine (including insomnia) were never followed up with large confirmatory trials despite initial exploratory studies 6. The 2020 VA/DoD guidelines explicitly recommend against using antipsychotics, including quetiapine, for chronic insomnia due to insufficient evidence and known harms 7.

Common pitfall: Patients and clinicians often assume that persistent side effects will resolve with time. With quetiapine's sedation, this assumption is incorrect—the drowsiness is the mechanism by which it helps sleep, and it doesn't disappear.

Bottom line: Your persistent drowsiness is expected, not abnormal. The solution is dose reduction and slower titration, not waiting for tolerance that won't develop. Consider discussing alternative evidence-based insomnia treatments with your prescriber, particularly if you're older or experiencing functional impairment from the sedation.